[Page Banner Image]

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available Sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

Dear Visitor,
We are taking a short vacation, enjoying the summer sunshine. The next update will appear in September.
Enjoy the rest of the summer and thank you for your cooperation.

[HRule Image]

Molecular Biology — June 2000

Antex Biologics has developed VEP (Virulence Expression Profiling) platform, a new genomics-based platform technology that reveals the blueprint of infectious bacteria in their host environment. VEP can duplicate in the laboratory the way bacteria grows in the human body and identify the disease-causing proteins of a bacteria at the genomic level.

Cell Genesys and the National Institutes of Health announced that in non-human primate models of hemophilia B, therapeutic levels of factor IX were restored following a single administration of hemophilia gene therapy. The therapy, which was delivered to the liver using the company's proprietary adeno-associated viral gene delivery system, was shown to be safe and well-tolerated in a variety of clinical assays. In addition, an immune response against the gene therapy, as measured by the development of anti-factor IX antibodies, was not observed.

ChromaVision Medical Systems, Inc. has introduced the new ACIS DNA Ploidy test to be run on the Automated Cellular Imaging System (ACIS). The test measures the DNA content within the nuclei of cancer cells, as a prognostic indicator in multiple cancer types. DNA Ploidy tests are a component of the primary panel of tests performed to characterize cancer tumors and determine the aggressiveness of those tumors.

Specialty Laboratories will be using SEQUENOM's MassARRAY system to perform genetic analyses to detect variations, or single nucleotide polymorphisms (SNPs), that are associated with specific diseases. In doing so, Specialty becomes the first U.S. diagnostics reference laboratory to use mass spectrometry for clinical diagnostics testing.

[HRule Image]

* Molecular Biology - May 2000
* Molecular Biology - April 2000
* Molecular Biology - March 2000
* Molecular Biology - Febuary 2000
* Molecular Biology - January 2000
* Molecular Biology - December 1999
* Molecular Biology - November 1999
* Molecular Biology - October 1999
* Molecular Biology - September 1999

[HRule Image]

Home | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Health Care in Canada
Information Technology and Healthcare | Molecular Biology | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-2000 STRATCOM

Last modified: July 3, 2000